Ability of a Cat Food to Reduce Respiratory Symptoms in Cat Allergic Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-05-06

Study Completion Date

2023-04-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cat allergy is the most common animal allergy, affecting approximately 1 in 5 adults worldwide. The prevalence of allergy to furry animals is increasing, and cat allergy is a major risk factor for the development of asthma and rhinitis.

Fel-d1 is the major feline allergen, to which 95% of cat allergic people react. All cats produce Fel-d1 regardless of breed, age, coat type, sex or weight. Fel-d1 is contained primarily in the saliva and sebum of cats.

This allergy manifests itself as allergic rhinitis (AR) (sneezing, cold, coughing, conjunctivitis with watering and itching), severe asthma, and irritation and swelling of the skin when scratched.

A new approach to managing cat allergies is to neutralize the allergens at the source by feeding domestic cats a diet containing anti-Fel-d1 IgY antibodies. The purpose of this pilot study is to determine whether feeding domestic cats a food containing an egg product with anti-Fel d1 IgY (PRO PLAN® LIVECLEAT®) induces a reduction of allergic symptoms in their owners.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat

NCT04981717

Allergic Rhinitis Due to Cat Allergy

TERMINATED PHASE3

Identification of Allergic Asthmatics Reactive to Felis Catus (Cat Hair) Allergen Inhalation

NCT03780387

Asthma Atopic

TERMINATED EARLY_PHASE1

Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge

NCT03838731

Cat Allergy Mild Asthma

COMPLETED PHASE2

Diesel Exhaust Particles and Leukotriene Production

NCT00915447

Allergic Rhinitis

WITHDRAWN

Effect of holoBLG on Cat Allergic Patients

NCT05455749

Allergy to Cats Allergic Rhinoconjunctivitis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rhinitis, Allergic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cats fed with PRO PLAN® LIVECLEAT®

Patient with domestic cats fed with an egg product containing anti-Fel d1 IgY (PRO PLAN® LIVECLEAT®)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Uncontrolled allergic rhinitis (with or without treatment)
* Persistent allergic rhinitis with worsening of symptoms upon exposure to cats
* Presence of one or two cats in the household, whose diet consists mainly of dry kibble
* Agreement of the patient to change the food of the cat(s) and to feed it exclusively with the test kibbles during the study.
* Diagnosis of cat allergy defined by a positive prick test to standardized cat allergen or cat-specific IgE.
* Absence of allergy to pollens emitted in the region during the 4 months following the inclusion date, confirmed by a negative skin test.
* Person owning an android and/or IOS smartphone and having the possibility to connect to the internet (via phone subscription or WIFI connection),
* Person who agrees to install the MASK-air application (medical device) on his personal smartphone,
* Person having read and understood the information note and having signed their participation agreement before any specific procedure of the study.

Exclusion Criteria

* Person planning to be away from the cat(s) for more than one week/month in the 4 months following the inclusion visit
* Patient who has had a new cat in the home for less than one month
* Patient in regular contact with other animals to which they are allergic
* Patient with uncontrolled asthma
* Patient receiving immunotherapy for cat allergies
* Patient participating or having participated in an allergic rhinitis study within the last 30 days or 5 half-lives of study medication
* Person who has difficulty understanding or reading the information
* Person declaring to be under guardianship, curatorship or safeguard of justice.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No